Literature DB >> 20201608

Efficacy and safety of the combined oral contraceptive ethinylestradiol/drospirenone (Yasmin) in healthy Chinese women: a randomized, open-label, controlled, multicentre trial.

Fan Guang-Sheng1, Bian Mei-Lu, Cheng Li-Nan, Cao Xiao-Ming, Huang Zi-Rong, Han Zi-Yan, Jing Xiao-Ping, Li Jian, Wu Shu-Ying, Xiong Cheng-Liang, Xiong Zheng-Ai, Yue Tian-Fu.   

Abstract

To evaluate and compare the contraceptive efficacy, bleeding pattern, side effects and other positive effects of a combined oral contraceptive (COC) containing drospirenone (DRSP) [Yasmin] with those of a COC containing desogestrel (DSG) in healthy Chinese women. This was a randomized, open-label, controlled, multicentre study of 768 healthy Chinese women requiring contraception. The subjects were randomized to ethinylestradiol (EE) 30 microg/DRSP 3 mg (n = 573) or EE 30 microg/ DSG 150 microg (n = 195), at a ratio of 3 : 1. Each individual was treated for 13 cycles. Further visits were required at cycle 4, cycle 7, cycle 10 and cycle 13 of treatment. Weight, height and body mass index were evaluated at each visit. The Menstrual Distress Questionnaire (MDQ) was administered at baseline, visit 3 (cycle 7) and visit 5 (after cycle 13). Baseline characteristics were similar between the two groups (p > 0.05). The Pearl Index (method failure) for EE/DRSP was 0.208 per 100 women-years, which was lower than that for EE/DSG (0.601 per 100 women-years). There were no significant differences between the treatment groups with regard to bleeding patterns. According to the MDQ subscale, improvements in water retention and increases in appetite during the intermenstrual period and in water retention and general well-being during the menstrual period in the EE/DRSP group (-0.297, -0.057, 0.033 and 0.150, respectively) were significantly improved compared with the EE/DSG group (-0.108, 0.023, 0.231 and -0.023, respectively) [all p < 0.05]. Other values that improved in both groups, particularly improvement in breast pain and tenderness and skin condition, were more evident in the EE/DRSP group (18.0%, 89/494; 12.6%, 62/494) than in the EE/DSG group (11.3%, 19/168; 5.4%, 9/168). Mean weight increased in the EE/DSG group (0.57 kg) while there was a significant decrease in mean weight (-0.28 kg) in the EE/DRSP group (p < 0.01). Both EE/DRSP and EE/DSG have good contraceptive efficacy and a comparable bleeding pattern. EE/DRSP had a more favourable effect on weight and premenstrual symptoms than EE/DSG.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20201608     DOI: 10.1007/bf03256908

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  15 in total

Review 1.  Pharmacology of different progestogens: the special case of drospirenone.

Authors:  R Sitruk-Ware
Journal:  Climacteric       Date:  2005-10       Impact factor: 3.005

Review 2.  Drospirenone in combination with estrogens: for contraception and hormone replacement therapy.

Authors:  W H K Oelkers
Journal:  Climacteric       Date:  2005-10       Impact factor: 3.005

Review 3.  Successful use of oral contraceptives.

Authors:  A E Burke; P D Blumenthal
Journal:  Semin Reprod Med       Date:  2001-12       Impact factor: 1.303

Review 4.  The premenstrual syndrome. A review.

Authors:  P M O'Brien
Journal:  J Reprod Med       Date:  1985-02       Impact factor: 0.142

5.  A new monophasic oral contraceptive containing drospirenone. Effect on premenstrual symptoms.

Authors:  Candace Brown; Frank Ling; Jim Wan
Journal:  J Reprod Med       Date:  2002-01       Impact factor: 0.142

6.  Conception and pharmacodynamic profile of drospirenone.

Authors:  Walter Elger; Sybille Beier; Kunhard Pollow; Robert Garfield; Shao Qing Shi; Alexander Hillisch
Journal:  Steroids       Date:  2003-11       Impact factor: 2.668

Review 7.  Pharmacology of estradiol valerate/dienogest.

Authors:  A Teichmann
Journal:  Climacteric       Date:  2003-08       Impact factor: 3.005

Review 8.  Drospirenone, a progestogen with antimineralocorticoid properties: a short review.

Authors:  Wolfgang Oelkers
Journal:  Mol Cell Endocrinol       Date:  2004-03-31       Impact factor: 4.102

9.  Serum levels of androgens are higher in women with premenstrual irritability and dysphoria than in controls.

Authors:  E Eriksson; C Sundblad; P Lisjö; K Modigh; B Andersch
Journal:  Psychoneuroendocrinology       Date:  1992 May-Jul       Impact factor: 4.905

Review 10.  Antimineralocorticoid activity of a novel oral contraceptive containing drospirenone, a unique progestogen resembling natural progesterone.

Authors:  W Oelkers
Journal:  Eur J Contracept Reprod Health Care       Date:  2002-12       Impact factor: 1.848

View more
  3 in total

1.  Does the presence of coexisting diseases modulate the effectiveness of a low-dose estrogen/progestin, ethinylestradiol/drospirenone combination tablet in dysmenorrhea? Reanalysis of two randomized studies in Japanese women.

Authors:  Mikio Momoeda; Masakane Hayakawa; Yukio Shimazaki; Hideki Mizunuma; Yuji Taketani
Journal:  Int J Womens Health       Date:  2014-12-02

2.  Effects of continuous-combined oral drospirenone- estradiol on blood pressure, body weight & lipid profile in early menopausal women.

Authors:  Aleksandar Đogo; Branko Dožić; Svetlana Vujović; Dragana Srebro; Ivan Dožić
Journal:  Indian J Med Res       Date:  2021-06       Impact factor: 5.274

3.  Needs and preferences of women users of oral contraceptives in selected countries in Central and Eastern Europe.

Authors:  Tomas Fait; Dmitry Buryak; Monica-Mihaela Cirstoiu; Eva Luczai; Rafal Janczura
Journal:  Drugs Context       Date:  2018-02-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.